Can we RESOLVE the treatment of sepsis?

This publication has 9 references indexed in Scilit:

• Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial
  The Lancet, 2007
• Microcirculatory disorders in sepsis and transplantation: therapy with natural coagulatory inhibitors antithrombin and activated protein C
  Current Opinion in Critical Care, 2006
• Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis
  Critical Care Medicine, 2006
• Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation
  Journal of Thrombosis and Haemostasis, 2006
• Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
  New England Journal of Medicine, 2005
• International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*
  Pediatric Critical Care Medicine, 2005
• Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
  Journal of Thrombosis and Haemostasis, 2004
• Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia*
  Critical Care Medicine, 2004
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001